Haleon plc (LON:HLN) Receives GBX 393.67 Average Price Target from Brokerages

Haleon plc (LON:HLN) has earned a consensus recommendation of “Hold” from the six research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is GBX 393.67.

Several brokerages recently issued reports on HLN. JPMorgan Chase & Co. dropped their price objective on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research note on Thursday, June 25th. Jefferies Financial Group decreased their target price on Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 370 price target on shares of Haleon in a research report on Thursday, April 30th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a GBX 325 price objective on shares of Haleon in a report on Wednesday, July 1st. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 512 price objective on shares of Haleon in a research note on Thursday, April 30th.

Haleon Price Performance

Haleon stock opened at GBX 370.87 on Thursday. The firm has a 50-day moving average price of GBX 343.97 and a 200-day moving average price of GBX 363.27. The firm has a market capitalization of £32.66 billion, a PE ratio of 20.05, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. Haleon has a 12-month low of GBX 317.80 and a 12-month high of GBX 416.10.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.